News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Corbus to host Sept 14 call to disclose topline CANYON-1 data for CRB-913 in obesity.
  • Cellectis will hold a Sept 14 webcast to provide a business update on its allogeneic CAR-T and gene therapy programs.
  • CEA Industries reported Q1 net loss of $11.4 million, driven by a $15.3 million unrealized loss on BNB tokens.
  • Biodexa posted a £1.84 million loss for H1 and flagged material uncertainty around future financing.
  • Impact BioMedical announced a 1-for-12.62 reverse split effective Sept 23 ahead of a planned merger with Zoar Ltd.
  • Star Bulk priced a €24.50 share offering with demand over six times allotment, indicating strong investor interest.

Latest Articles

MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets

MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets

MicroCloud Hologram Inc. announced the acquisition of 140,268 shares of MicroStrategy Incorporated (MSTR) common stock through the maturity and settlement of a structured note investment product worth approximately $15.76 million. The company views this as a strategic move to strengthen its position in Bitcoin and digital asset-related opportunitie…

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical to jointly commercialize two biosimilar candidates—AVT34 (biosimilar to Imfinzi®) and AVT87 (biosimilar to Hemlibra®)—in the United States and selected Asian markets. The deal includes semi-exclusive U.S. rights for both companies and exclusive rights…

iRhythm: Algorithmic Margin Inflection Makes This a Tactical Long

iRhythm: Algorithmic Margin Inflection Makes This a Tactical Long

iRhythm is entering a different profit cycle. Revenue growth remains healthy while algorithm-driven margin expansion — not new hardware — is the clearest lever to lift profitability. Market skepticism after product delays and a cyber incident creates an actionable asymmetric trade. We outline a mid-term (45 trading days) long with concrete levels a…

Marvell’s Rally: Valuation Questions as Oppenheimer Raises Target to $300

Marvell’s Rally: Valuation Questions as Oppenheimer Raises Target to $300

Oppenheimer raised its Marvell Technology (MRVL) price target to $300 from $250, suggesting about 19.5% upside from the prevailing $251.01 share price. The upgrade centers on a structural artificial intelligence thesis in which custom ASIC revenue is expected to double to more than $4 billion next year and to surpass $10 billion by calendar year 20…

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Group, trading on NYSE American as SBEV, is changing its name to Endovia Health Sciences, Inc. and adopting a new ticker symbol, EDVA, starting August 24, 2026. This rebranding reflects the company’s strategic transformation from beverage operations into a diversified cannabinoid-based health sciences platform. Endovia focuses on th…

Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset

Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset

Quantum X Labs announced enhanced performance of its AI-assisted quantum error-correction decoder using Google’s public surface-code dataset from real quantum hardware. The decoder, trained exclusively on synthetic data, outperformed benchmark algorithms, supporting the company’s progress toward reliable, scalable, and real-time quantum error corre…

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RenovoRx, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement after its stock price remained at or above $1.00 for 10 consecutive business days. This milestone follows the company's record quarterly revenue, expanded commercial uptake of its FDA-cleared RenovoCath drug-delivery device, and full enrollment in the Ph…

reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform

reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform

reAlpha Tech Corp. has completed its acquisition of InstaMortgage Inc., a multi-state mortgage lender. This acquisition integrates direct lending capabilities into reAlpha's platform, enabling the company to originate, underwrite, and fund mortgages in-house across 38 states and Washington, D.C. The move aims to create a seamless end-to-end homebuy…

Amazon Clearance: Buying the Dip in Cloud-Driven Momentum

Amazon Clearance: Buying the Dip in Cloud-Driven Momentum

Amazon shares pulled back into the low $260s on profit-taking, presenting a tradeable buying opportunity. AWS is the profit engine with a $496B backlog and management is prioritizing capacity buildout with massive capex. Valuation sits at a reasonable ~21x earnings for a business generating strong ROE; this trade targets a rebound toward the $285 a…

Brandywine Realty Trust Announces Upsize and Extension of Expiration of the Previously Announced Tender Offer for the 2029 Notes

Brandywine Realty Trust Announces Upsize and Extension of Expiration of the Previously Announced Tender Offer for the 2029 Notes

Brandywine Realty Trust announced an increase in the aggregate principal amount it will accept in its cash tender offer for its 2029 Notes from $50 million to $70 million. The expiration date for the tender offer was extended from August 21 to August 25, 2026. Terms include a tender offer consideration of $1,068.75 per $1,000 principal amount tende…

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Milestone Pharmaceuticals initiated the ReVeRA-301 Phase 3 trial to evaluate the safety and efficacy of etripamil nasal spray as a self-administered treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR). Building on FDA approval of etripamil for PSVT and promising Phase 2 results, the trial aims to reduce reliance on emergency ca…

GDEV announces results for the second quarter and first half of 2026

GDEV announces results for the second quarter and first half of 2026

GDEV Inc. announced its unaudited financial results for Q2 and first half of 2026, reporting a 22% revenue decrease in Q2 and 11% for H1 2026 compared to 2025, primarily due to lower bookings and paying users. Despite revenue declines, the company improved net profit and operating cash flows in both periods by reducing marketing expenses and optimi…

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Ambros Therapeutics and Werewolf Therapeutics have entered into an all-stock merger agreement to create a Nasdaq-listed late-stage biotech company focused on developing neridronate, a potential first FDA-approved treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1). Concurrent with the merger, they secured $150 million in an oversubscribed …

Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives

Springbig Completes Reorganization, Eliminating Approximately $12.5 Million of Secured Debt and Positioning SBIG to Explore Strategic Alternatives

SpringBig Holdings, Inc. has completed a reorganization that eliminated approximately $12.5 million in secured debt by transferring ownership of its former operating subsidiary to an entity designated by secured lenders. Now operating as a streamlined, debt-free public company, SpringBig is evaluating multiple strategic opportunities aimed at incre…